8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Apr 15, 2026·SEC
Wave Life Sciences Ltd.(WVE)Earnings, Financials & Key Ratios
WVE•NASDAQ
Price updated Jun 11, 2026
AboutWave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.Show more
- Revenue$43M-60.5%
- EBITDA-$207M-103.0%
- Net Income-$204M-110.7%
- EPS (Diluted)-1.21-72.9%
- Gross Margin79.28%-20.7%
- EBITDA Margin-483.37%-414.6%
- Operating Margin-504.09%-394.5%
- Net Margin-478.33%-434.0%
- ROE-55.56%+28.7%
- Debt/Equity0.03-72.2%
WVE Key Insights
Wave Life Sciences Ltd. (WVE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 16.3%
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 15 (bottom 15%)
- ✗Shares diluted 22.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when WVE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
WVE Price & Volume
Wave Life Sciences Ltd. (WVE) stock price & volume — 10-year historical chart
Loading chart...
WVE Growth Metrics
Wave Life Sciences Ltd. (WVE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years75.75%
5 Years16.31%
3 Years127.08%
TTM-31.58%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-63.44%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-26.19%
Return on Capital
10 Years-85.67%
5 Years-87.8%
3 Years-68.37%
Last Year-54.9%
WVE Recent Earnings
Wave Life Sciences Ltd. (WVE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
Apr 28, 2026EPS
$0.13
Est $0.34
+61.8%
Revenue
$38M
Est $8M
+352.6%
Q1 2026
Feb 26, 2026EPS
$0.30
Est $0.28
-7.1%
Revenue
$17M
Est $16M
+7.4%
Q4 2025
Nov 10, 2025EPS
$0.32
Est $0.30
-6.7%
Revenue
$8M
Est $16M
-53.5%
Q3 2025
Jul 30, 2025EPS
$0.31
Est $0.29
-6.9%
Revenue
$9M
Est $10M
-11.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.13vs $0.34+61.8% | $38Mvs $8M+352.6% |
| Q1 2026 | Feb 26, 2026 | $0.30vs $0.28-7.1% | $17Mvs $16M+7.4% |
| Q4 2025 | Nov 10, 2025 | $0.32vs $0.30-6.7% | $8Mvs $16M-53.5% |
| Q3 2025 | Jul 30, 2025 | $0.31vs $0.29-6.9% | $9Mvs $10M-11.7% |
Based on last 12 quarters of dataView full earnings history →
WVE Peer Comparison
Wave Life Sciences Ltd. (WVE) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 1.58B | 15.00 | -2.10 | 15.58% | 2.98% | 4.89% | 0.91 | |
 IONS | 12.2B | 73.82 | -31.02 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ARWR | 10.48B | 74.41 | -6099.18 | 232.58% | -48.38% | -55.09% | 0.73 | |
 NTLA | 1.39B | 12.35 | -3.24 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.02B | 29.41 | -36.31 | 120.01% | -49.17% | -5.89% | 0.24 | |
 PRQR | 151.72M | 1.44 | -3.28 | -19.18% | -339.41% | -86.47% | 0.28 | |
 ALNY | 38.61B | 289.39 | 124.20 | 65.19% | 13.46% | 98.29% | 1.62 | |
 REGN | 63.53B | 611.48 | 14.74 | 0.99% | 29.65% | 14.32% | 0.09 |
Compare WVE vs Peers
Wave Life Sciences Ltd. (WVE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
WVE Income Statement
Wave Life Sciences Ltd. (WVE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 3.7M | 14.41M | 15.98M | 20.08M | 40.96M | 3.65M | 113.31M | 108.3M | 42.73M | 71.8M |
Revenue Growth % | 149.43% | 289.15% | 10.89% | 25.61% | 104.03% | -91.09% | 3005.1% | -4.42% | -60.55% | -31.58% |
Cost of Goods Sold | 79.31M | 134.43M | 175.43M | 130.94M | 0 | 0 | 0 | 0 | 8.85M | 4.46M |
COGS % of Revenue | 2141.17% | 932.62% | 1097.61% | 652.21% | - | - | - | - | 20.72% | - |
Gross Profit | -75.61M▲ 0% | -120.01M▼ 58.7% | -159.45M▼ 32.9% | -110.87M▲ 30.5% | 40.96M▲ 136.9% | 3.65M▼ 91.1% | 113.31M▲ 3005.1% | 108.3M▼ 4.4% | 33.88M▼ 68.7% | 67.34M▲ 0% |
Gross Margin % | -2041.17% | -832.62% | -997.61% | -552.21% | 100% | 100% | 100% | 100% | 79.28% | 93.79% |
Gross Profit Growth % | -7023.53% | -58.74% | -32.86% | 30.47% | 136.95% | -91.09% | 3005.1% | -4.42% | -68.72% | - |
Operating Expenses | 106.28M | 173.94M | 48.87M | 42.51M | 167.98M | 166.37M | 181.3M | 218.71M | 249.26M | 264.22M |
OpEx % of Revenue | 2869.44% | 1206.72% | 305.76% | 211.73% | 410.07% | 4559.3% | 160.01% | 201.94% | 583.37% | - |
Selling, General & Admin | 26.98M | 39.51M | 48.87M | 42.51M | 46.1M | 50.51M | 51.29M | 59.02M | 75.33M | 79.08M |
SG&A % of Revenue | 728.27% | 274.1% | 305.76% | 211.73% | 112.55% | 1384.3% | 45.27% | 54.5% | 176.31% | - |
Research & Development | 79.31M | 134.43M | 175.43M | 130.94M | 121.88M | 115.86M | 130.01M | 159.68M | 182.78M | 189.6M |
R&D % of Revenue | 2141.17% | 932.62% | 1097.61% | 652.21% | 297.52% | 3175.01% | 114.74% | 147.44% | 427.78% | - |
Other Operating Expenses | -331K | 9.55M | -175.43M | -130.94M | 0 | 0 | 0 | 0 | -8.85M | -2M |
Operating Income | -102.58M▲ 0% | -159.52M▼ 55.5% | -208.32M▼ 30.6% | -153.38M▲ 26.4% | -127.02M▲ 17.2% | -162.72M▼ 28.1% | -68M▲ 58.2% | -110.4M▼ 62.4% | -215.38M▼ 95.1% | -196.88M▲ 0% |
Operating Margin % | -2769.44% | -1106.72% | -1303.37% | -763.94% | -310.07% | -4459.3% | -60.01% | -101.94% | -504.09% | -274.21% |
Operating Income Growth % | -85.41% | -55.51% | -30.59% | 26.37% | 17.19% | -28.11% | 58.21% | -62.37% | -95.09% | - |
EBITDA | -100.42M | -153.94M | -200.73M | -145.26M | -117.18M | -152.61M | -58.79M | -101.74M | -206.53M | -187.88M |
EBITDA Margin % | -2711.26% | -1068% | -1255.89% | -723.53% | -286.06% | -4182.13% | -51.89% | -93.94% | -483.37% | -261.68% |
EBITDA Growth % | -84.12% | -53.29% | -30.39% | 27.63% | 19.33% | -30.23% | 61.48% | -73.06% | -103% | -60.45% |
D&A (Non-Cash Add-back) | 2.15M | 5.58M | 7.59M | 8.11M | 9.84M | 10.11M | 9.21M | 8.66M | 8.85M | 8.99M |
EBIT | -102.39M | -159.52M | -208.32M | -153.38M | -127.02M | -162.72M | -68M | -110.4M | -204.38M | -191.09M |
Net Interest Income | 6K | 22K | 0 | -16K | 30K | 0 | 0 | 0 | 10.48M | 12.89M |
Interest Income | 0 | 0 | - | 0 | 30K | 0 | 0 | 0 | 10.48M | 12.89M |
Interest Expense | 6K | 22K | - | 16K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.25M | 12.94M | 14.68M | 2.63M | 4.57M | 1.58M | 9.81M | 13.39M | 11.01M | 13.29M |
Pretax Income | -101.33M▲ 0% | -146.58M▼ 44.7% | -193.64M▼ 32.1% | -150.75M▲ 22.1% | -122.45M▲ 18.8% | -161.14M▼ 31.6% | -58.19M▲ 63.9% | -97.01M▼ 66.7% | -204.38M▼ 110.7% | -183.59M▲ 0% |
Pretax Margin % | -2735.61% | -1016.96% | -1211.52% | -750.86% | -298.92% | -4416.06% | -51.36% | -89.57% | -478.33% | -255.7% |
Income Tax | 708K | 69K | 0 | -841K | -204K | 681K | -677K | 0 | 0 | 0 |
Effective Tax Rate % | -0.7% | -0.05% | 0% | 0.56% | 0.17% | -0.42% | 1.16% | 0% | 0% | 0% |
Net Income | -102.03M▲ 0% | -146.65M▼ 43.7% | -193.64M▼ 32.0% | -149.91M▲ 22.6% | -122.25M▲ 18.5% | -161.82M▼ 32.4% | -57.51M▲ 64.5% | -97.01M▼ 68.7% | -204.38M▼ 110.7% | -183.59M▲ 0% |
Net Margin % | -2754.72% | -1017.43% | -1211.52% | -746.68% | -298.42% | -4434.72% | -50.76% | -89.57% | -478.33% | -255.7% |
Net Income Growth % | -84.18% | -43.73% | -32.04% | 22.58% | 18.45% | -32.38% | 64.46% | -68.67% | -110.68% | -63.44% |
Net Income (Continuing) | -101.98M | -146.65M | -193.64M | -149.91M | -122.25M | -161.82M | -57.51M | -97.01M | -204.38M | -183.59M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -3.85▲ 0% | -5.06▼ 31.4% | -5.30▼ 4.7% | -3.82▲ 27.9% | -2.36▲ 38.2% | -2.05▲ 13.1% | -0.54▲ 73.7% | -0.70▼ 29.6% | -1.21▼ 72.9% | -0.92▲ 0% |
EPS Growth % | -58.44% | -31.43% | -4.74% | 27.92% | 38.22% | 13.14% | 73.66% | -29.63% | -72.86% | -26.19% |
EPS (Basic) | -3.85 | -5.06 | -5.30 | -3.82 | -2.36 | -2.05 | -0.54 | -0.70 | -1.21 | - |
Diluted Shares Outstanding | 26.51M | 28.97M | 33.87M | 39.23M | 51.83M | 78.86M | 106.1M | 138.28M | 168.65M | 200.17M |
Basic Shares Outstanding | 26.51M | 28.97M | 33.87M | 39.23M | 51.83M | 78.86M | 106.1M | 138.28M | 168.65M | 200.17M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
WVE Balance Sheet
Wave Life Sciences Ltd. (WVE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 150.49M | 202.27M | 185.48M | 230.04M | 162.56M | 98.54M | 235.37M | 320.39M | 614.81M | 561.27M |
Cash & Short-Term Investments | 142.5M | 174.82M | 147.16M | 184.5M | 150.56M | 88.5M | 200.35M | 302.08M | 602.07M | 544.59M |
Cash Only | 142.5M | 174.82M | 147.16M | 184.5M | 150.56M | 88.5M | 200.35M | 302.08M | 602.07M | 544.59M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1M | 10M | 20M | 30M | 0 | 0 | 21.09M | 1.42M | 1.28M | 0 |
Days Sales Outstanding | 98.54 | 253.23 | 456.74 | 545.4 | - | - | 67.93 | 4.79 | 10.9 | 16.39 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 10.87M | 8.69M | 5.11M | 5.42M | 2.11M | 4.02M | 7.35M | 11.47M | 16.68M |
Total Non-Current Assets | 31.36M | 93.67M | 98.77M | 49.2M | 44.44M | 47.85M | 39.58M | 31.81M | 23.68M | 22.27M |
Property, Plant & Equipment | 27.33M | 39.93M | 54.47M | 45.43M | 40.64M | 44.13M | 35.72M | 28M | 19.86M | 18.07M |
Fixed Asset Turnover | 0.14x | 0.36x | 0.29x | 0.44x | 1.01x | 0.08x | 3.17x | 3.87x | 2.15x | 3.41x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 3.61M | 53.63M | 33.65M | 3.65M | 0 | 0 | 0 | 0 | 3.81M | 7.62M |
Other Non-Current Assets | 411K | 111K | 10.66M | 115K | 3.8M | 3.72M | 3.85M | 3.81M | 16K | 386K |
Total Assets | 181.84M▲ 0% | 295.94M▲ 62.7% | 284.25M▼ 4.0% | 279.24M▼ 1.8% | 207.01M▼ 25.9% | 146.39M▼ 29.3% | 274.95M▲ 87.8% | 352.21M▲ 28.1% | 638.5M▲ 81.3% | 583.54M▲ 0% |
Asset Turnover | 0.02x | 0.05x | 0.06x | 0.07x | 0.20x | 0.02x | 0.41x | 0.31x | 0.07x | 0.17x |
Asset Growth % | 10.33% | 62.74% | -3.95% | -1.76% | -25.87% | -29.28% | 87.82% | 28.1% | 81.29% | 171.84% |
Total Current Liabilities | 19.62M | 130.04M | 118.15M | 121.04M | 64.2M | 71.52M | 186.44M | 110.95M | 95.06M | 49.83M |
Accounts Payable | 7.6M | 13.09M | 9.07M | 13.79M | 7.28M | 16.91M | 12.84M | 16.26M | 15.7M | 19.06M |
Days Payables Outstanding | 34.97 | 35.54 | 18.88 | 38.45 | - | - | - | - | 647.37 | 1.31K |
Short-Term Debt | 0 | 1.16M | 3.24M | 3.71M | 0 | 0 | 0 | 0 | 8.36M | 8.33M |
Deferred Revenue (Current) | 2.71M | 100.94M | 89.65M | 91.56M | 37.1M | 31.56M | 150.06M | 65.97M | 44.44M | 151.94M |
Other Current Liabilities | 1.33M | 6.47M | 7.52M | 2.97M | 10.18M | 12.29M | 14.06M | 15.36M | 26.56M | 13.04M |
Current Ratio | 7.67x | 1.56x | 1.57x | 1.90x | 2.53x | 1.38x | 1.26x | 2.89x | 6.47x | 11.26x |
Quick Ratio | 7.67x | 1.56x | 1.57x | 1.90x | 2.53x | 1.38x | 1.26x | 2.89x | 6.47x | 11.26x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.29K |
Total Non-Current Liabilities | 22.41M | 92.55M | 94.49M | 67.55M | 110.31M | 119.96M | 48.88M | 31.74M | 17.2M | 21.98M |
Long-Term Debt | 3.09M | 9.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 3.09M | 9.25M | 29.3M | 25.59M | 24.95M | 32.12M | 25.4M | 17.77M | 9.4M | 41.74M |
Deferred Tax Liabilities | 1.37M | 68.16M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 10.61M | 5.9M | 1.72M | 474K | 7.87M | 8.06M | 7.87M | 7.87M | 0 | 0 |
Total Liabilities | 42.03M | 222.59M | 212.64M | 188.59M | 174.51M | 191.48M | 235.32M | 142.69M | 112.27M | 71.81M |
Total Debt | 3.45M | 10.4M | 32.55M | 29.3M | 29.92M | 37.61M | 32.12M | 25.4M | 17.77M | 15.71M |
Net Debt | -139.05M | -164.42M | -114.61M | -155.19M | -120.65M | -50.88M | -168.23M | -276.67M | -584.3M | -528.88M |
Debt / Equity | 0.02x | 0.14x | 0.45x | 0.32x | 0.92x | - | 0.81x | 0.12x | 0.03x | 0.03x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.08x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 2.81x |
Interest Coverage | -17065.17x | -7251.05x | - | -9586.06x | - | - | - | - | - | - |
Total Equity | 139.81M▲ 0% | 73.35M▼ 47.5% | 71.61M▼ 2.4% | 90.65M▲ 26.6% | 32.5M▼ 64.2% | -45.09M▼ 238.8% | 39.63M▲ 187.9% | 209.51M▲ 428.7% | 526.23M▲ 151.2% | 511.73M▲ 0% |
Equity Growth % | 3.67% | -47.54% | -2.38% | 26.6% | -64.15% | -238.75% | 187.89% | 428.68% | 151.17% | 3399.62% |
Book Value per Share | 5.27 | 2.53 | 2.11 | 2.31 | 0.63 | -0.57 | 0.37 | 1.52 | 3.12 | 2.56 |
Total Shareholders' Equity | 139.81M | 73.35M | 71.61M | 90.65M | 32.5M | -45.09M | 39.63M | 209.51M | 526.23M | 511.73M |
Common Stock | 310.04M | 375.15M | 539.55M | 694.09M | 749.85M | 802.83M | 935.37M | 1.18B | 1.62B | 1.63B |
Retained Earnings | -192.51M | -339.72M | -533.36M | -683.27M | -805.51M | -967.34M | -1.02B | -1.12B | -1.33B | -1.35B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 116K | 153K | 267K | 389K | 181K | -29K | -124K | -262K | -250K | -254K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
WVE Cash Flow Statement
Wave Life Sciences Ltd. (WVE) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -83.67M | -22.86M | -188.23M | -115.98M | -88.99M | -127.78M | -19.43M | -151.03M | -187.49M | -182.35M |
Operating CF Margin % | -2258.94% | -158.61% | -1177.7% | -577.69% | -217.25% | -3501.81% | -17.15% | -139.45% | -438.82% | - |
Operating CF Growth % | -162.52% | 72.68% | -723.34% | 38.38% | 23.27% | -43.59% | 84.79% | -677.24% | -24.15% | -31.68% |
Net Income | -102.03M | -146.65M | -193.64M | -149.91M | -122.25M | -161.82M | -57.51M | -97.01M | -204.38M | -183.59M |
Depreciation & Amortization | 2.15M | 5.58M | 9.2M | 9.98M | 9.84M | 10.11M | 9.21M | 8.66M | 8.85M | 8.15M |
Stock-Based Compensation | 12.14M | 15.6M | 19.51M | 14.3M | 16.41M | 17.19M | 9.79M | 13.14M | 0 | 21.73M |
Deferred Taxes | 774K | 44K | 0 | -9.14M | -12.64M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 3.59M | 183K | 0 | 9.14M | 12.64M | 12K | 0 | 0 | 24.97M | 9.43M |
Working Capital Changes | -299K | 102.39M | -23.3M | 9.65M | 7.01M | 6.72M | 19.08M | -75.82M | -16.94M | -38.08M |
Change in Receivables | -1M | -59M | 10M | 20M | 30M | 0 | -21.09M | 19.66M | 146K | 177.78K |
Change in Inventory | 0 | -4.08M | 0 | 4.61M | 2.04M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 3.89M | 4.94M | -3.5M | 5.12M | -6.57M | 9.35M | -3.76M | 3.42M | -561K | 4.81M |
Cash from Investing | -18.9M | -9.94M | -3.92M | -1.34M | -560K | -1.25M | -1.11M | -938K | -718K | -981.99K |
Capital Expenditures | -18.89M | -9.94M | -3.92M | -1.34M | -560K | -1.36M | -1.11M | -938K | -718K | -273K |
CapEx % of Revenue | 509.91% | 68.95% | 24.51% | 6.66% | 1.37% | 37.3% | 0.98% | 0.87% | 1.68% | 0.38% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -9K | -9.94M | 0 | 0 | 0 | 106K | 0 | 0 | 0 | -708.99K |
Cash from Financing | 94.37M | 65.09M | 164.4M | 154.54M | 55.83M | 67.19M | 132.53M | 253.89M | 488.24M | 489.54M |
Debt Issued (Net) | -62K | -16K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 93.51M | 60M | 161.79M | 153.63M | 54.97M | 52.33M | 131.28M | 236.18M | 488.24M | 486.47M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 927K | 5.11M | 2.61M | 912K | 858K | 14.86M | 1.26M | 17.71M | 0 | 3.07M |
Net Change in Cash | -7.79M▲ 0% | 32.33M▲ 515.0% | -27.64M▼ 185.5% | 37.34M▲ 235.1% | -33.93M▼ 190.9% | -62.06M▼ 82.9% | 111.89M▲ 280.3% | 101.79M▼ 9.0% | 300.04M▲ 194.8% | 301.55M▲ 0% |
Free Cash Flow | -102.56M▲ 0% | -32.8M▲ 68.0% | -192.15M▼ 485.8% | -117.32M▲ 38.9% | -89.55M▲ 23.7% | -129.14M▼ 44.2% | -20.55M▲ 84.1% | -151.96M▼ 639.6% | -187.49M▼ 23.4% | -183.34M▲ 0% |
FCF Margin % | -2768.84% | -227.56% | -1202.21% | -584.35% | -218.61% | -3539.11% | -18.13% | -140.31% | -438.82% | -255.35% |
FCF Growth % | -173.93% | 68.02% | -485.82% | 38.94% | 23.67% | -44.21% | 84.09% | -639.63% | -23.38% | -1.11% |
FCF per Share | -3.87 | -1.13 | -5.67 | -2.99 | -1.73 | -1.64 | -0.19 | -1.10 | -1.11 | -0.92 |
FCF Conversion (FCF/Net Income) | 0.82x | 0.16x | 0.97x | 0.77x | 0.73x | 0.79x | 0.34x | 1.56x | 0.92x | 1.00x |
Interest Paid | 37K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 11K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
WVE Key Ratios
Wave Life Sciences Ltd. (WVE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -74.29% | -137.6% | -267.17% | -184.78% | -198.53% | - | -145.12% | -77.87% | -55.56% | -56.41% |
| Return on Invested Capital (ROIC) | -10056.86% | - | - | - | - | - | - | - | - | 338.24% |
| Gross Margin | -2041.17% | -832.62% | -997.61% | -552.21% | 100% | 100% | 100% | 100% | 79.28% | 93.79% |
| Net Margin | -2754.72% | -1017.43% | -1211.52% | -746.68% | -298.42% | -4434.72% | -50.76% | -89.57% | -478.33% | -255.7% |
| Debt / Equity | 0.02x | 0.14x | 0.45x | 0.32x | 0.92x | - | 0.81x | 0.12x | 0.03x | 0.03x |
| Interest Coverage | -17065.17x | -7251.05x | - | -9586.06x | - | - | - | - | - | - |
| FCF Conversion | 0.82x | 0.16x | 0.97x | 0.77x | 0.73x | 0.79x | 0.34x | 1.56x | 0.92x | 1.00x |
| Revenue Growth | 149.43% | 289.15% | 10.89% | 25.61% | 104.03% | -91.09% | 3005.1% | -4.42% | -60.55% | -31.58% |
Related:WVE Dividend History·WVE Revenue History·WVE Price History·WVE P/E History·WVE Financial Ratios·WVE Institutional Holders
WVE SEC Filings & Documents
Wave Life Sciences Ltd. (WVE) SEC filings — annual & quarterly reports (10-K, 10-Q)
WVE Frequently Asked Questions
Wave Life Sciences Ltd. (WVE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Wave Life Sciences Ltd. (WVE) reported $71.8M in revenue for fiscal year 2025.
Wave Life Sciences Ltd. (WVE) saw revenue decline by 60.5% over the past year.
Wave Life Sciences Ltd. (WVE) reported a net loss of $183.6M for fiscal year 2025.
Dividend & Returns
Wave Life Sciences Ltd. (WVE) has a return on equity (ROE) of -55.6%. Negative ROE indicates the company is unprofitable.
Wave Life Sciences Ltd. (WVE) had negative free cash flow of $183.3M in fiscal year 2025, likely due to heavy capital investments.